cystic fibrosis

pharma-news-for-vertex-tonix-quoin

Dec 24, 2024

FDA Approves Vertex’s ALYFTREK for Cystic Fibrosis; ZEPBOUND Gets FDA Approval for Obstructive Sleep Apnea in Obese Adults; Tonix’s TNX-102 SL NDA Accepted for Fibromyalgia; Quoin’s QRX003 Clears FDA for Netherton Syndrome Study; FDA Approves First Mesenchymal Stromal Cell Therapy for Acute GvHD

applications-of-organoids-in-healthcare

Nov 06, 2024

6 Groundbreaking Applications of Organoids That Are Changing Healthcare

bacteriophage-based-cystic-fibrosis-treatment

Jan 12, 2024

Is Bacteriophage a Potential Game-Changer in the Realm of Cystic Fibrosis Treatment?

Pharma News for Sanofi, Sosei, AstraZeneca, Arcturus

Nov 28, 2023

Dupixent Significantly Reduced COPD Exacerbations; Sosei Heptares to Regain Ownership of GSK4381406; AstraZeneca Gains Rights to Usynova’s KRAS Inhibitor; FDA Approvs OGSIVEO for Desmoid Tumors; Orphan Drug Designation for ARCT-032 for the Cystic Fibrosis; FDA Fast Track Designation for ADP101 for Food Allergies

Delveinsight

Dec 13, 2022

Amgen to Purchase Horizon Therapeutics; IND Clearance to Vertex’s VX-522; FDA Fast-Track Designation for Moleculin’s WP1122; Orphan Drug Designation to Brim’s WP1122; Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study; UCB Announces Phase 3 Studies for Bimekizumab

chronic-respiratory-disease-crd-prevalence-and-treatment-options

May 26, 2021

Alarming Growth of Chronic Respiratory Diseases (CRDs) and Their Prolonged Impact on the Quality of Life

Pharma happenings for Urovant's vibegron Genmab and Polyphor

Nov 26, 2020

Cancer-killing virus flees immune destruction and attacks metastatic lung tumors; Urovant’s vibegron fails trial; Genmab discards antibody-drug conjugate; Polyphor picks up $3.3M for inhaled antibiotic

Pharma News

Mar 26, 2020

FDA permits COVID-19 treatment, Roche’s antibiotics pact, Moderna’s vaccine, FDA permits Remdesivir, ReCode needs USD 80 Million

NTM infection drug pipeline

Feb 10, 2020

Bridging the gap: Nontuberculous mycobacterium Infections Drug Pipeline

Nontuberculous Mycobacteria Infection

Feb 03, 2020

Lack of effective therapy: A major Nontuberculous Mycobacteria Infection Market Driver

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper